IL242760B - A Biomimetic Peptide and Biodegradable Delivery Platform for the Treatment of Angiogenesis and Lymphangiogenesis-Dependent Diseases - Google Patents

A Biomimetic Peptide and Biodegradable Delivery Platform for the Treatment of Angiogenesis and Lymphangiogenesis-Dependent Diseases

Info

Publication number
IL242760B
IL242760B IL242760A IL24276015A IL242760B IL 242760 B IL242760 B IL 242760B IL 242760 A IL242760 A IL 242760A IL 24276015 A IL24276015 A IL 24276015A IL 242760 B IL242760 B IL 242760B
Authority
IL
Israel
Prior art keywords
lymphangiogenesis
angiogenesis
treatment
delivery platform
dependent diseases
Prior art date
Application number
IL242760A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of IL242760B publication Critical patent/IL242760B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
IL242760A 2013-06-07 2015-11-24 A Biomimetic Peptide and Biodegradable Delivery Platform for the Treatment of Angiogenesis and Lymphangiogenesis-Dependent Diseases IL242760B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361832290P 2013-06-07 2013-06-07
PCT/US2014/041526 WO2014197892A1 (en) 2013-06-07 2014-06-09 A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases

Publications (1)

Publication Number Publication Date
IL242760B true IL242760B (en) 2021-03-25

Family

ID=52008639

Family Applications (1)

Application Number Title Priority Date Filing Date
IL242760A IL242760B (en) 2013-06-07 2015-11-24 A Biomimetic Peptide and Biodegradable Delivery Platform for the Treatment of Angiogenesis and Lymphangiogenesis-Dependent Diseases

Country Status (11)

Country Link
US (4) US9802984B2 (OSRAM)
EP (2) EP3643318A1 (OSRAM)
JP (2) JP6470740B2 (OSRAM)
CN (2) CN105431162B (OSRAM)
AU (1) AU2014274703B2 (OSRAM)
CA (1) CA2914764C (OSRAM)
DK (1) DK3003343T3 (OSRAM)
ES (1) ES2774217T3 (OSRAM)
HU (1) HUE047735T2 (OSRAM)
IL (1) IL242760B (OSRAM)
WO (1) WO2014197892A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9802984B2 (en) * 2013-06-07 2017-10-31 The Johns Hopkins University Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
WO2016022947A1 (en) 2014-08-07 2016-02-11 The Johns Hopkins University Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
EP3377080B1 (en) * 2015-11-19 2024-02-14 Asclepix Therapeutics, LLC Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
CN110177563A (zh) * 2016-10-04 2019-08-27 阿斯克雷佩西治疗公司 用于激活tie2信号传导的化合物和方法
US20200179285A1 (en) * 2017-05-08 2020-06-11 The Johns Hopkins University Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
WO2019028427A1 (en) * 2017-08-03 2019-02-07 Asclepix Therapeutics, Llc. METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR
WO2019075056A1 (en) 2017-10-10 2019-04-18 The Johns Hopkins University BIODEGRADABLE BIOMIMETIC PARTICLES
US11697804B2 (en) 2018-10-01 2023-07-11 The Johns Hopkins University Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy
EP3920894A4 (en) * 2019-02-06 2022-11-09 The University of North Carolina at Chapel Hill COMPOSITIONS AND METHODS TO INHIBIT POSTOPERATIVE ADHESIONS
US20230054032A1 (en) * 2019-03-26 2023-02-23 Asclepix Therapeutics, Inc. Compositions and methods for treating ocular disease
CN113144213B (zh) * 2021-03-23 2023-04-07 西安交通大学医学院第一附属医院 一种多级pH响应基因-药物共递送的纳米药物、制备方法及其应用
WO2024044745A2 (en) * 2022-08-26 2024-02-29 Asclepix Therapeutics, Inc. Formulations for intraocular delivery of peptides derived from type iv collagen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2015781A4 (en) 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
AU2007239095B2 (en) * 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
ITMI20060625A1 (it) * 2006-03-31 2007-10-01 Istituto Naz Per La Ricerca Peptide antiangiogenico e suoi impieghi terapeutici
JP2010509369A (ja) * 2006-11-10 2010-03-25 ジェネンテック インコーポレイテッド 加齢黄斑変性症を処置するための方法
US8507434B2 (en) * 2007-01-03 2013-08-13 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
BRPI0912536A2 (pt) * 2008-05-06 2018-10-16 Glaxo Group Ltd método para produzir um carregador particulado, carreador particulado, composição farmacêutica, e, e uso da mesma.
WO2010010551A2 (en) 2008-07-21 2010-01-28 Compugen Ltd. Novel angiopoietin derived peptides
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
IN2012DN05099A (OSRAM) * 2009-12-16 2015-10-09 Brigham & Womens Hospital
US20120192339A1 (en) 2010-07-28 2012-08-02 Honeywell International Inc. Flexible Body Armor Vest with Breast Plate
US20120270770A1 (en) * 2010-08-03 2012-10-25 Jesse Michael Jaynes Anti-angiogenic peptides and their uses
EP2649095B1 (en) 2010-12-10 2021-10-06 Aleksander S. Popel Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
CN103547639B (zh) 2011-02-24 2016-08-17 柯尼卡美能达株式会社 活性光线固化型喷墨油墨及图像形成方法
WO2014066811A1 (en) 2012-10-25 2014-05-01 The Johns Hopkins University Bioreducible poly (b-amino ester)s for sirna delivery
WO2014066898A1 (en) 2012-10-26 2014-05-01 The Johns Hopkins University A layer-by-layer approach to co-deliver dna and sirna via aunps: a potential platform for modifying release kinetics
US9802984B2 (en) * 2013-06-07 2017-10-31 The Johns Hopkins University Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases

Also Published As

Publication number Publication date
US10774112B2 (en) 2020-09-15
AU2014274703A1 (en) 2015-12-10
AU2014274703B2 (en) 2019-07-04
US9802984B2 (en) 2017-10-31
US20200361993A1 (en) 2020-11-19
CN110981941A (zh) 2020-04-10
JP2019089790A (ja) 2019-06-13
HK1222542A1 (zh) 2017-07-07
JP6931011B2 (ja) 2021-09-01
JP6470740B2 (ja) 2019-02-13
US11981754B2 (en) 2024-05-14
US20180134753A1 (en) 2018-05-17
US20240391957A1 (en) 2024-11-28
ES2774217T3 (es) 2020-07-17
EP3643318A1 (en) 2020-04-29
WO2014197892A1 (en) 2014-12-11
CN105431162B (zh) 2019-12-10
JP2016521712A (ja) 2016-07-25
EP3003343B1 (en) 2019-10-23
EP3003343A4 (en) 2016-11-30
HUE047735T2 (hu) 2020-05-28
US20160122390A1 (en) 2016-05-05
CN105431162A (zh) 2016-03-23
EP3003343A1 (en) 2016-04-13
CA2914764A1 (en) 2014-12-11
DK3003343T3 (da) 2020-02-03
CA2914764C (en) 2021-10-26

Similar Documents

Publication Publication Date Title
IL242760B (en) A Biomimetic Peptide and Biodegradable Delivery Platform for the Treatment of Angiogenesis and Lymphangiogenesis-Dependent Diseases
IL274646A (en) Integrated continuous production of medicinal substances from medical protein
IL250660A0 (en) Skin sensors for drug delivery devices
IL285716A (en) Compacted molecules derived from colic toxin for oral delivery of a biologically active payload
IL244259A0 (en) Insertion of medical devices
ZA201702634B (en) Therapeutic agent delivery device
IL241811B (en) A system for creating sprays that includes a source of compound that enhances delivery and a source of drug
IL240849A0 (en) Drug delivery devices and drug delivery method
SG11201508180PA (en) Prosthetic heart valve delivery apparatus
IL247795B (en) tco couplings and methods for shipping medical materials
SG11201609966SA (en) Drug delivery system and method of use
GB201515650D0 (en) Medicament delivery devices
PL3234107T3 (pl) Limfocyty b do dostarczania in vivo środków terapeutycznych
EP3183026A4 (en) Implants for localized drug delivery and methods of use thereof
SG11201608483PA (en) Drug delivery systems and related methods of use
IL254625A0 (en) Device for targeted delivery of a therapeutic implant
ZA201603117B (en) Withanolides useful for the treatment of neurodegenerative diseases
EP3136840A4 (en) Aided delivery of plant treatment agents
IL248904B (en) Peptide-polypeptide composite nanoparticles for use in drug delivery
GB201419540D0 (en) Delivery of drugs
GB201410507D0 (en) Drug delivery enhancement agents
GB201511126D0 (en) Spray device for the delivery of therapeutic agents
GB201319437D0 (en) Delivery of drugs
GB201304999D0 (en) Composition and method of implantable devices for localized delivery of bioactive compounds
GB201607794D0 (en) Medicament delivery devices

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed